Drugs for Gout
October 30, 2023 (Issue: 1688)
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
- JD FitzGerald et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020; 72:744. doi:10.1002/acr.24180
- A Meaidi et al. Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study. BMJ 2023; 382:e074450. doi:10.1136/bmj-2022-074450
- Inhibitors and inducers of CYP enzymes and P-glycoprotein and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- In brief: New warnings on NSAID use in pregnancy. Med Lett Drugs Ther 2020; 62:175.
- BS Wiggins et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2016; 134:e468. doi:10.1161/cir.0000000000000456
- LR Sammaritano et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken) 2020; 72:461. doi:10.1002/acr.24130
- CA Billy et al. Corticosteroid or nonsteroidal antiinflammatory drugs for the treatment of acute gout: a systematic review of randomized controlled trials. J Rheumatol 2018; 45:128. doi:10.3899/jrheum.170137
- MD Wechalekar et al. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 2013; 4:CD009920. doi:10.1002/14651858.cd009920.pub2
- G Bandoli et al. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am 2017; 43:489. doi:10.1016/j.rdc.2017.04.013
- Canakinumab (Ilaris) for systemic juvenile idiopathic arthritis. Med Lett Drugs Ther 2013; 55:65.
- N Schlesinger et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839. doi:10.1136/annrheumdis-2011-200908
- P Ghosh et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013; 65:1381. doi:10.1002/acr.21989
- TJ Major et al. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ 2018; 363:k3951. doi:10.1136/bmj.k3951
- T Neogi et al. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study. Am J Med 2014; 127:311. doi:10.1016/j.amjmed.2013.12.019
- SM Nielsen et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis 2017; 76:1870. doi:10.1136/annrheumdis-2017-211472
- AB Vargas-Santos et al. Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med 2018; 178:1526. doi:10.1001/jamainternmed.2018.4463
- Febuxostat (Uloric) for chronic treatment of gout. Med Lett Drugs Ther 2009; 51:37.
- FDA Drug Safety Communication. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). February 21, 2019. Available at: www.fda.gov/Drugs/DrugSafety/ucm631182.htm. Accessed October 12, 2023.
- H Yu et al. Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study. Clin Exp Nephrol 2018; 22:1324. doi:10.1007/s10157-018-1586-y
- KG Saag et al. Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo-controlled study. Arthritis Rheumatol 2019; 71:143. doi:10.1002/art.40685
- WB White et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018; 378:1200. doi:10.1056/nejmoa1710895
- IS Mackenzie et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 2020; 396:1745. doi:10.1016/s0140-6736(20)32234-0
- ME Kleber et al. Uric acid and cardiovascular events: a Mendelian randomization study. J Am Soc Nephrol 2015; 26:2831. doi:10.1681/asn.2014070660
- H-W Park et al. Efficacy of the HLA-B*58:01 screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency-A prospective study. J Allergy Clin Immunol Pract 2019; 7:1271. doi:10.1016/j.jaip.2018.12.012
- I Kamilli and U Gresser. Allopurinol and oxypurinol in human breast milk. Clin Investig 1993; 71:161. doi:10.1007/bf00179999
- KF Ilett et al. Transfer of probenecid and cephalexin into breast milk. Ann Pharmacother 2006; 40:986. doi:10.1345/aph.1g580
- Pegloticase (Krystexxa) for treatment of refractory gout. Med Lett Drugs Ther 2011; 53:9.
- JS Sundy et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306:711. doi:10.1001/jama.2011.1169
- HS Baraf et al. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol 2014; 20:427. doi:10.1097/rhu.0000000000000200
- LH Calabrese et al. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. Arthritis Res Ther 2017; 19:191. doi:10.1186/s13075-017-1396-8
- JK Botson et al. Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR). J Rheumatol 2021; 48:767. doi:10.3899/jrheum.200460
- PP Khanna et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2021; 73:1523. doi:10.1002/art.41731
- S Takahashi et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62:572. doi:10.1136/ard.62.6.572
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
